Rochelle Lewis has joined millions of women pushing for a name change for polycystic ovary syndrome (PCOS), a condition affecting over 170 million women worldwide. The BBC Health report examines how renaming the disorder could shift both medical understanding and patient outcomes.
PCOS carries significant stigma tied to its current name. The term emphasizes cysts on ovaries, a symptom present in only some patients, while obscuring the condition's core metabolic dysfunction. Many women report delayed diagnoses because doctors fixate on reproductive issues rather than addressing insulin resistance, hormonal imbalance, and systemic inflammation that characterize the disease.
Lewis and other advocates argue that renaming PCOS would better reflect the endocrine and metabolic reality of the condition. A more accurate name could accelerate clinical research, improve diagnostic protocols, and destigmatize the experience for the millions of women managing it. The current nomenclature particularly fails women of color and those outside reproductive years, who face compounded diagnostic barriers.
The push for renaming PCOS joins broader medical efforts to update outdated terminology. Similar campaigns have successfully reframed other conditions, leading to improved recognition and treatment pathways. For PCOS specifically, changing the name could prompt physicians to screen for metabolic complications like type 2 diabetes and cardiovascular disease earlier in patient care.
Lewis's case underscores how language shapes medicine. A condition renamed to reflect metabolic dysfunction rather than ovarian appearance could fundamentally alter how clinicians approach diagnosis and management, ultimately benefiting the 170 million women living with PCOS globally.